💊 ยา A-Z 🧬 เป้าหมาย 🛠 เครื่องมือ 📚 คู่มือ
ยาทั้งหมด หมวดหมู่ยา ด้านการรักษา ผลข้างเคียง
คู่มือ อภิธานศัพท์ ไทม์ไลน์
การเปรียบเทียบ เส้นทางของยา กลุ่มยา
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Tralokinumab

CHEMBL1743081 Phase 4 ได้รับการอนุมัติ Antibody
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Tralokinumab is a fully human monoclonal antibody that specifically neutralizes interleukin-13 (IL-13), a key Th2 cytokine that drives skin barrier disruption, sensitization, and chronic inflammation in atopic dermatitis and contributes to airway inflammation in asthma. By blocking IL-13 from binding to its receptor, it reduces eosinophilic inflammation, IgE production, and epithelial barrier dysfunction. It is approved for moderate-to-severe atopic dermatitis in adults inadequately controlled by topical therapies.

ด้านการรักษา

Asthma Psoriasis Atopic Dermatitis

กลไกการออกฤทธิ์

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

Tralokinumab is a fully human monoclonal antibody that specifically neutralizes interleukin-13 (IL-13), a key Th2 cytokine that drives skin barrier disruption, sensitization, and chronic inflammation in atopic dermatitis and contributes to airway inflammation in asthma. By blocking IL-13 from binding to its receptor, it reduces eosinophilic inflammation, IgE production, and epithelial barrier dysfunction. It is approved for moderate-to-severe atopic dermatitis in adults inadequately controlled by topical therapies.

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

Yes, Tralokinumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1743081. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.